Background: Abdominal aortic aneurysm (AAA) is usually asymptomatic and mostly diagnosed incidentally. Aortic dilatation progresses along with the wall weakening and eventually leads to a life-threatening rupture. Currently, there are no effective screening biomarkers for AAA. MicroRNAs, a class of small noncoding RNA molecules, offer great potential as biomarkers because of their stability in the bloodstream and expression profile specific for different diseases.
Objective: To assess the circulating miR-29c-3p as a potential biomarker of AAA and to elucidate the biological functions of miR-29c-3p in terms of pathogenesis of aneurysms.
Methods: Two groups of patients scheduled for elective surgery were studied: 52 patients with AAA, and 51 patients with peripheral artery disease who served as a control group (matched by age and gender). Serum miRNA was measured for circulating miR-29c-3p using quantitative real-time PCR. Functional tests of miR-29c-3p impact on the targeted transcripts were studied using its mimic or inhibitor and a cell culture of endothelial cells.
Results: Serum miR-29c-3p was significantly elevated in AAA patients as compared with controls (RQ=8.73) and correlated with the diameter of the aneurysm. No association between well-known risk factors and level of circulating miR-29c-3p was found using a logistic regression. In vitro study revealed that miR-29c-3p suppressed transcripts of ELN, COL4A1, PTEN and VEGFA.
Conclusion: The results suggest that elevated miR-29c-3p is a potential serum biomarker for AAA. Causal involvement of miR-29c-3p in pathogenesis of the disease was found in human vascular endothelial cells, which extracellular matrix synthesis and integrity maintenance was inhibited.
Keywords: Abdominal aortic aneurysm, endothelium epigenetics, microRNA biomarker, miR-29c-3p, non coding RNA, serum miRNA.
Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry 3D Reconstruction of a Primary Aortoenteric Fistula – Centerline Calculation and Measurements
Current Medical Imaging Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Phase Image in the Detection of Myocardial Dyskinesia by Magnetic Resonance Imaging (MRI)
Current Medical Imaging Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Evaluation of Application Value of Transcranial Doppler (TCD) in the Inspection of Cerebral Vasospasm After the Treatment of Intracranial Aneurysm
Current Medical Imaging Imaging of Abdominal Aortic Aneurysm: The Present and the Future
Current Vascular Pharmacology Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms
Current Drug Targets Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Inflammatory Cells and Proteases in Abdominal Aortic Aneurysm and its Complications
Current Drug Targets Problems and Perspectives of Abdominal Aortic Aneurysm Research
Current Drug Targets Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Ruptured Bronchial Artery Aneurysm Treated With Aortic Stent Graft and Aneurysm Embolization
Current Medical Imaging Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research The Effect of Nicotine and Tobacco on Aortic Matrix Metalloproteinases in the Production of Aortic Aneurysm
Current Vascular Pharmacology